On Friday, Shares of General Electric Company (NYSE:GE), lost -2.08% to $24.
General Electric Company Capital’s Healthcare Financial Services (HFS) business declared recently that it served as administrative agent on a $55 million senior credit facility to recapitalize the Community Intervention Services, Inc. (CIS) balance sheet, support CIS’s acquisition of Futures Behavior Therapy Center, LLC and provide additional capacity for targeted acquisitions. GE Capital Markets served as sole lead arranger and bookrunner on the transaction.
CIS, based in Austin, TX, is a leading provider of behavioral health services that cares for more than 50,000 patients annually. CIS was established by private equity firm H.I.G. Growth Partners, in partnership with behavioral healthcare executive Kevin Sheehan, to acquire, develop and operate a national network of specialized behavioral health treatment facilities and programs.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -2.47% to $57.30, during its last trading session.
Bristol-Myers Squibb Company declared updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase 1b trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). In this study, Opdivo was administered as monotherapy or as part of a combination with other agents, counting Yervoy, at different doses and plans. Results from other cohorts in CheckMate -012 have been formerly-unstated. These updated results comprise findings from the administration of four new dosing plans of Opdivo+Yervoy (n=148), which resulted in confirmed objective response rates (ORR) ranging from 13% to 39% depending on the administered regimen. Median duration of response was not reached in any of these arms with a median follow-up of 6.2 months to 16.6 months, and median progression-free survival (PFS) ranged from 4.9 months to 10.6 months.
The types of treatment-related serious adverse events (SAEs) stated in these cohorts for CheckMate -012 were consistent with other formerly-stated Opdivo+Yervoy cohorts of this trial. The new dosing plans in this study resulted in less toxicity than formerly-stated dosing plans, and were characterized by low frequency of treatment-related adverse events (AEs) leading to discontinuation (3% to 10%) and no treatment-related deaths. These data will be presented today at the 16th World Conference on Lung Cancer (WCLC) (Abstract #786).
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Morgan Stanley (NYSE:MS), ended its last trade with -1.80% loss, and closed at $33.19.
Eric Heaton, President of Morgan Stanley’s U.S. banks, will speak at the Barclays Global Financial Services Conference in New York on Friday, September 18, 2015, at 10:30 a.m. Eastern Time.
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
